Table 3. Responder Analyses for DLQI, EQ-5D-5L, and HADS.
| Variable | % | |
|---|---|---|
| Week 16 | Week 52 | |
| MCID-based DLQI responders (exploratory outcomes) | ||
| Risankizumab | 94.5 | 96.3 |
| Ustekinumab | 85.1 | 84.6 |
| Placebo | 35.6 | NA |
| P value risankizumab vs ustekinumab | <.001 | <.001 |
| P value risankizumab vs placebo | <.001 | NA |
| DLQI = 0/1 responders (ranked secondary outcomes) | ||
| Risankizumab | 66.2 | 73.1 |
| Ustekinumab | 44.7 | 45.7 |
| Placebo | 6.0 | NA |
| P value risankizumab vs ustekinumab | <.001 | <.001 |
| P value risankizumab vs placebo | <.001 | NA |
| MCID-based EQ-5D-5L responders (exploratory outcomes) | ||
| Risankizumab | 41.7 | 44.4 |
| Ustekinumab | 31.5 | 32.0 |
| Placebo | 19.0 | NA |
| P value risankizumab vs ustekinumab | .01 | .002 |
| P value risankizumab vs placebo | <.001 | NA |
| MCID-based HADS anxiety scale responders (exploratory outcomes) | ||
| Risankizumab | 69.1 | 65.5 |
| Ustekinumab | 57.1 | 60.4 |
| Placebo | 35.9 | NA |
| P value risankizumab vs ustekinumab | .004 | .25 |
| P value risankizumab vs placebo | <.001 | NA |
| MCID-based HADS depression scale responders (exploratory outcomes) | ||
| Risankizumab | 71.1 | 68.9 |
| Ustekinumab | 60.4 | 66.7 |
| Placebo | 37.1 | NA |
| P value risankizumab vs ustekinumab | .01 | .67 |
| P value risankizumab vs placebo | <.001 | NA |
| HADS anxiety scale (<8) (exploratory outcomes) | ||
| Risankizumab | 82.1 | 81.6 |
| Ustekinumab | 73.2 | 79.8 |
| Placebo | 61.5 | NA |
| P value risankizumab vs ustekinumab | .009 | .65 |
| P value risankizumab vs placebo | <.001 | NA |
| HADS depression scale (<8) (exploratory outcomes) | ||
| Risankizumab | 89.3 | 89.8 |
| Ustekinumab | 85.4 | 89.4 |
| Placebo | 70.5 | NA |
| P value risankizumab vs ustekinumab | .17 | .98 |
| P value risankizumab vs placebo | <.001 | NA |
Abbreviations: DLQI, Dermatology Life Quality Index; EQ-5D-5L, 5-level EuroQoL-5D; HADS, Hospital Anxiety and Depression Scale; MCID, minimal clinically important difference; NA, not applicable.